Biopsy endoscopy platform unlocks $18B advanced treatmentopportunities
OnePass has developed InstaFANTM – a patented multi-needle platform device that can be used for biopsy collection and for delivering targeted therapies to pancreatic and liver cancer patients.
The Need
Pancreatic tumor is currently the 3rd most common cause of cancer-related deaths in the US and is expected to be the 2nd most common cause by 2030.
EUS-guided FNA (EUS-FNA) is an established technique for tissue acquisition and is considered the most sensitive and accurate diagnostic procedure for the evaluation of malignant and benign pancreatic lesions. However, Pancreatic EUS-FNA diagnosis has a false negative rate ranging up to 20-40% of cases due to sampling error, in the case of pancreatic cancer this translates to patient death in 95% of the cases.
In most cases the tumor is benign and the patient is being invited routinely for monitoring because those tumors tend to turn malignant and when that is happening the patient is being invited to surgery – those surgeries are considered high risk and the physicians tends to avoid it as much as possible.
***
Jacob BenArie, co founder and CEO, MBA, BSc
Former CEO, Orgenesis (Nasdaq: ORGS) Betalin, BetaStim, Q2Pharma
Prof. Jesse Lachter MD, co-founder and Chief Medical Officer
Gastroenterologist, former Head of EUS, Service, Rambam, Health Care Campus
Ms. Netta Deutschman, CPA, Chief Financial Officer
10 years of experience in the high-tech startup’s scene and with the Israel Innovation Authority’s funding programs and regulation
Prof. Ron Epelbaum, MD, Clinical Research Manager
Oncologist, former director of the division of cancer, Rambam Health Care
Motti Attia, Marketing Manager
GTM expert with more than 15 years of experience as a marketing manager
Yaron Amikam, M.Sc. Engineering Manager
Former Dev. & Engineering Manager at HanitaLenses and Elcam Medical